-
Electronic (PDF)
-
CD ROM
-
1 - 5 Users
-
Site License
-
Enterprisewide
Oncology Partnering Terms and Agreements
CurrentPartnering, January 2013, Pages: 1117
The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in oncology partnering deals
- Average deal terms for headline, upfront and royalty by stage of development
- Oncology partnering agreement structure
- Oncology partnering contract documents
- Top oncology deals by value
- Most active oncology dealmakers
The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 2,700 links to online copies of actual oncology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading oncology deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.
Report scope
Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.
Oncology Partnering Terms and Agreements includes:
- Trends in oncology dealmaking in the biopharma industry since 2007
- Analysis of oncology deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life oncology deals
- Access to over 2,700 oncology contract documents
- The leading oncology deals by value since 2007
- Most active oncology dealmakers since 2007
- The leading oncology partnering resources
In Oncology Partnering Terms and Agreements, the available contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Oncology Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 2,700 oncology deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise oncology rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Oncology Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of oncology deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,700 actual oncology contracts entered into by the world’s biopharma companies
- Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a oncology agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in oncology dealmaking
2.1. Introduction
2.2. Oncology partnering over the years
2.3. Bigpharma oncology dealmaking activity
2.4. Bigpharma not active in oncology
2.5. Oncology partnering by deal type
2.6. Oncology partnering by industry sector
2.7. Oncology partnering by stage of development
2.8. Oncology partnering by technology type
2.9. Oncology partnering by oncology indication
2.10. Average deal terms for oncology
2.10.1 Oncology headline values
2.10.2 Oncology upfront payments
2.10.3 Oncology milestone payments
2.10.4 Oncology royalty rates
Chapter 3 – Leading oncology deals
3.1. Introduction
3.2. Top oncology deals by value
3.3. Top oncology deals involving bigpharma
Chapter 4 – Bigpharma oncology deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma oncology partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
Valeant
Watson
Chapter 5 – Oncology partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
5.3. By stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
5.4. By technology type
Analysis
Animal models
Antibodies
Assays
Bioinformatics
Biological compounds
Biomarkers
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Implant
Industrial chemicals
In vitro models
Nanotechnology
Natural product
Oligonucleotide
Orphan drug
Peptides
Personalised medicine
Pharmacogenomics
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Software tools
Stem cells
Vaccines
Chapter 6 – Oncology dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Oncology
Adenocarcinoma
Basal cell carcinoma
Bile duct cancer
Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
Esophageal cancer
Gastric cancer
Head and neck cancer
Kaposi's sarcoma
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Small cell lung cancer
Lymphoma
Hodgkin's lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Bone metastases
Multiple myeloma
Neuroblastoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Non-melanoma skin cancer
Solid tumors
Symptoms
Alopecia
Cachexia
Cancer pain
Neuropathic
Chemotherapy
Dysphagia
Lymphoedema
Nausea
Oral mucositis
Radiotherapy
Vomiting
Testicular cancer
Thyroid cancer
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Appendices
Appendix 1 – Directory of oncology deals by company A-Z 2007-2013
Appendix 2 – Directory of oncology deals by deal type 2007-2013
Appendix 3 – Directory of oncology deals by stage of development 2007-2013
Appendix 4 – Directory of oncology deals by technology type 2007-2013
Appendix 5 – Deal type definitions
Table of figures
Figure 1: Oncology partnering since 2007
Figure 2: Bigpharma – top 50 – Oncology deals 2007 to 2012
Figure 3: Bigpharma oncology deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in oncology 2007-2013
Figure 5: Oncology partnering by deal type since 2007
Figure 6: Oncology partnering by industry sector since 2007
Figure 7: Oncology partnering by stage of development since 2007
Figure 8: Oncology partnering by technology type since 2007
Figure 9: Oncology partnering by oncology target since 2007
Figure 10: Oncology deals with a headline value
Figure 11: Oncology deal headline value distribution, US$million – discovery stage
Figure 12: Oncology deal headline value distribution, US$million – preclinical stage
Figure 13: Oncology deal headline value distribution, US$million – phase I stage
Figure 14: Oncology deal headline value distribution, US$million – phase II stage
Figure 15: Oncology deal headline value distribution, US$million – phase III stage
Figure 16: Oncology deal headline value distribution, US$million – regulatory stage
Figure 17: Oncology deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2013
Figure 19 Oncology deals with upfront payment values
Figure 20: Oncology deal upfront payment distribution, US$million – discovery stage
Figure 21: Oncology deal upfront payment distribution, US$million – preclinical stage
Figure 22: Oncology deal upfront payment distribution, US$million – phase I stage
Figure 23: Oncology deal upfront payment distribution, US$million – phase II stage
Figure 24: Oncology deal upfront payment distribution, US$million – phase III stage
Figure 25: Oncology deal upfront payment distribution, US$million – regulatory stage
Figure 26: Oncology deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2013
Figure 28: Oncology deals with milestone payments
Figure 29: Oncology deal milestone distribution, US$million – discovery stage
Figure 30: Oncology deal milestone distribution, US$million – preclinical stage
Figure 31: Oncology deal milestone distribution, US$million – phase I stage
Figure 32: Oncology deal milestone distribution, US$million – phase II stage
Figure 33: Oncology deal milestone distribution, US$million – phase III stage
Figure 34: Oncology deal milestone distribution, US$million – regulatory stage
Figure 35: Oncology deal milestone distribution, US$million – marketed stage
Figure 36: Oncology deals with royalty rates, %
Figure 37: Oncology deal royalty rate distribution, US$million – discovery stage
Figure 38: Oncology deal royalty rate distribution, US$million – preclinical stage
Figure 39: Oncology deal royalty rate distribution, US$million – phase I stage
Figure 40: Oncology deal royalty rate distribution, US$million – phase II stage
Figure 41: Oncology deal royalty rate distribution, US$million – phase III stage
Figure 42: Oncology deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2013
Figure 45: Top oncology deals by value since 2007
Figure 46: Top oncology deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
